Dermira to Present at the 8th Annual SVB Leerink Global Healthcare Conference
February 21, 2019 16:01 ET
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Report Fourth Quarter 2018 Results and Host Conference Call on Tuesday, February 26, 2019
February 19, 2019 16:01 ET
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab
February 12, 2019 02:00 ET
|
Dermira, Inc.
- Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe- Dermira to receive an option fee of $30 million- Lebrikizumab is an...
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 11, 2018 17:07 ET
|
Dermira, Inc.
MENLO PARK, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Enters into Credit Facility with Athyrium Capital Management
December 04, 2018 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Present at Evercore ISI HealthCONx Conference
November 19, 2018 08:00 ET
|
Dermira, Inc.
MENLO PARK, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 08, 2018 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Reports Third Quarter 2018 Financial Results
November 07, 2018 16:01 ET
|
Dermira, Inc.
Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing...
Dermira to Report Third Quarter 2018 Results and Host Conference Call on Wednesday, November 7, 2018
October 31, 2018 16:01 ET
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
October 23, 2018 16:01 ET
|
Dermira, Inc.
Topline efficacy and safety results anticipated by early April 2019 MENLO PARK, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company...